Sai Parenterals Ltd will host a meeting with analysts and institutional investors on October 14, 2026. The event is scheduled to begin at 11:00 am at the company's facilities in Hyderabad.

The company filed this intimation with the BSE and NSE on October 1, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the disclosure of schedules for analyst and institutional investor meetings.

Meeting details

The interaction will take place at the corporate office in Hyderabad. The company stated that discussions will be based exclusively on publicly available information.

Disclosure compliance

Sai Parenterals confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. The filing was signed by Anil Kumar Karusala, Managing Director of the company.

The company noted that changes to the schedule may occur due to exigencies on the part of participants or the company itself.

Sai Parenterals Limited announced significant changes to its senior management structure following a board meeting held on September 30, 2026. The company accepted the resignation of Shivali Aggarwal as Company Secretary and Compliance Officer while simultaneously appointing Ashwani Singh Bisht to the same role and Arvind Gannimitta as the new Chief Operating Officer.

The transition ensures continuity in key managerial personnel (KMP) and operational leadership. Aggarwal’s resignation, initially communicated in August 2026 with an effective date on or before October 12, 2026, was approved by the board to take effect immediately from September 30, 2026. This accelerated timeline marks the immediate commencement of duties for her successor.

New appointments take effect immediately

Ashwani Singh Bisht has been appointed as the Company Secretary and Compliance Officer, designated as Key Managerial Personnel. He brings over 12 years of professional experience, including more than 5 years in corporate secretarial and compliance functions. A qualified member of the Institute of Company Secretaries of India (ICSI), Bisht has handled secretarial matters for both listed and unlisted companies and possesses exposure to merchant banking activities.

Arvind Gannimitta joins as the Chief Operating Officer, serving as Senior Management Personnel. He holds a Ph.D. in Pharmaceuticals and has over 26 years of extensive experience in pharmaceutical operations. His background includes managing manufacturing functions and overseeing regulatory requirements within the industry.

Leadership profile summary

The board meeting, which commenced at 10:30 am and concluded at 11:45 am, was held at the company’s registered office in Hyderabad. These appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that there are no inter-director relationships among the newly appointed officers.